The 13-Valent Pneumococcal Conjugate Vaccine Elicits Serological Response and Lasting Protection in Selected Patients With Primary Humoral Immunodeficiency

BACKGROUND: Patients with primary humoral immunodeficiency are more prone to invasive as well as recurrent pneumococcal infections. Therefore, anti-pneumococcal vaccination including the 13-valent conjugate vaccine is recommended. Nevertheless, to date, no data is available on immunogenicity of this...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Front Immunol
Prif Awduron: Robbins, Ailsa, Bahuaud, Mathilde, Hentzien, Maxime, Maestraggi, Quentin, Barbe, Coralie, Giusti, Delphine, Le Naour, Richard, Batteux, Frederic, Servettaz, Amélie
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Frontiers Media S.A. 2021
Pynciau:
Immunology
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC8287634/
https://ncbi.nlm.nih.gov/pubmed/34290713
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2021.697128
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg